REQUEST FOR INFORMATION:

HOST-DIRECTED THERAPEUTICS

Objective:

This is a Request for Information (RFI) for planning purposes only. It is not to be construed as a commitment by the Government nor will the Government pay for the information solicited. No solicitation document exists or is guaranteed to be issued as a result of this RFI. The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) under the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) is seeking information on the available capabilities and willingness of private entities (academic, non-profit, and commercial) to collaborate with the Government in the areas listed below.

Background:

The Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) is performing market-based research and is requesting information from product developers who develop medical countermeasures to protect and/or treat the warfighter who may be infected with or exposed to biological agents.

The JPEO-CBRND is interested in late-stage development of host-directed therapeutics or repurposing of United States Food and Drug Administration (FDA) licensed therapeutics that are threat-agnostic with the potential for activity across viral or toxin families. The candidate(s) should have demonstrated activity targeting the patient's immune response to infection or illness caused by viruses or toxins. The ideal candidate would be a small molecule with enhanced stability that can be easily administered by either ingestion, inhalation or intramuscular injection. Development and clinical testing of vaccines will not be considered in this request.

Requirements:

The Respondents shall provide the following in reply to this RFI, not to exceed 2 pages in total:

1. Host-Directed Therapeutic Capability Description (1 page maximum)
   - Description and discussion of any candidates that are threat-agnostic with the potential for activity across viral or toxin families. Include the mechanism of action and formulation.
   - Discussion of the maturity of the proposed candidate, including previous demonstrated use, and any relevant FDA regulatory exposure.
   - Provide a brief description of company history, alliances and funding emphasizing experience in advanced development including non-clinical studies, clinical experience and manufacturing capability. Include planned partners.

2. Quad chart (1 page maximum)
   a. Detail key programmatic goals, high-level timeline, and budget for future product development, including the following:
      - Objective of the project and benefits of the product
      - High-level development schedule with major goals/milestones
      - Rough Order of Magnitude cost
      - Any associated intellectual property rights, patent coverage, or data rights assertions

Administration:

The Government will retain comments and information received in response to this RFI. Proprietary information should be identified as Company Proprietary. Do not use Government security classification markings. All written responses must be received by 30 May 2025, 1600, EDST. Responses should be sent by e-mail to: MCDC@ati.org, with Subject Line denoting the Responding Organization and RFI Title. Material that is advertisement only in nature is not desired. If a solicitation is subsequently released based on the responses to this RFI, the first choice for an acquisition vehicle, if appropriate, will be an Other Transaction Agreement (OTA) issued either bilaterally via publicly posted Request for Prototype Proposal (RPP), and/or an RPP issued under the Medical CBRN Defense Consortium (MCDC). Respondents not already members of the MCDC are encouraged to join at www.medcbrn.org. Respondents may also inquire about the MCDC at mcdc@ati.org.